TRANSVAC2: Improving and accelerating vaccine development in Europe

AT A GLANCE...

TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC2 is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of vaccine projects by implementing a permanent research infrastructure, for vaccine development.

AIMS

- Support innovation for prophylactic and therapeutic vaccine development for both human and veterinary use with strong emphasis on a collaborative one-health approach
- Accelerate vaccine development by developing & applying cutting-edge technologies
- Offer training courses to provide fundamental and advanced knowledge in vaccinology
- Develop a sustainable vaccine infrastructure accelerating vaccine R&D

TRAINING MODULES

TRANSVAC2 training subjects range from analytical research-oriented techniques, clinical and process development to regulatory aspects.

SERVICES & TRAININGS

Next calls

Services: TNA1910-7 TNA2002-8 TNA2006-9 TNA2010-10
Trainings: TR19106 TR20027 TR20068 TR20108
For more information on open calls and submission deadlines visit transvac2.org

TRANSVAC2 IN NUMBERS, SO FAR...

Services

5 TNA Application calls
38 Applications
55% Success rate

Trainings

4 Application calls
114 Applications
75% Success rate

Our Partners

Visit transvac2.org Get updates on open calls, services and training opportunities. subscribe to TRANSVAC mailing list or follow European Vaccine Initiative or

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 730964.

“TRANSVAC2, supporting the present and transforming the future of vaccine R&D landscape in Europe, while creating global (health) impact.”